A Randomized, Double-masked, Active-controlled, Multi-center Phase 2 Clinical Study Evaluating the Efficacy and Safety of 0.5% and 1.0% VVN461 Ophthalmic Solution in Patients with Noninfectious Anterior Uveitis
Latest Information Update: 17 Nov 2024
Price :
$35 *
At a glance
- Drugs VVN 461 (Primary) ; Prednisolone acetate
- Indications Uveitis
- Focus Therapeutic Use
- Sponsors VivaVision Biotech
- 13 Nov 2024 New trial record